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ABSTRACT: Rhinoviruses (RVs) have been recently associated with exacerbations of many 
pulmonary diseases, thus increasing morbidity and/or mortality in subjects at risk. Unfortunately, 
the wide variety of RV genotypes constitutes a major hindrance for the development of 
rhinovirus replication inhibitors. In the current investigation, we develop a novel series of 
pyrazolic derivatives that potently inhibits rhinovirus replication. Compounds 10e and 10h act as 
early stage inhibitors of rhinovirus infection with a broad-spectrum activity against RV-A and 
RV-B species (EC50 < 0.1 µM). We have also evaluated the dynamics of resistance emergence of 
these promising compounds and their in vitro genotoxicity. Molecular docking experiments shed 
light on the pharmacophoric elements interacting with residues of the drug-binding pocket.  
INTRODUCTION 
Rhinoviruses (RVs) are among the most common viruses worldwide. With a respiratory tract 
tropism, these infectious agents of the Picornaviridae family (genus Enterovirus) are the major 
causative agents of upper respiratory tract infections.1,2 Besides being the etiological agent of the 
“common cold”, they are also associated with acute otitis media (AOM) development in 
pediatric populations,3,4,5 and sinusitis.6,7 Since a decade, RVs are known to cause exacerbations 
of chronic pulmonary diseases in infants, elderly, and immunocompromised patients.8,9 RVs 
have a strong impact on the morbidity and the mortality related to asthma in these 
populations.10,11,12,13 Also, it has been reported that RV infections lead to worsening of chronic 
obstructive pulmonary disease (COPD),14,15 and cystic fibrosis.16,17 Up to date, more than three 
hundred million people are suffering from chronic pulmonary illnesses. Industrial and academic 
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laboratories are therefore reviving research against rhinoviruses in order to provide therapeutic 
solutions. 
As commonly observed in the Picornavirales order, RVs are composed of a positive-sense 
single-stranded RNA surrounded with a protein shell called the capsid. To date, 167 types of 
rhinovirus have been identified by molecular-based phylogenetics and classified in three species, 
namely RV-A, RV-B, and RV-C.18,19 Following entry, viral RNA is translated into a single 
polyprotein, which is further processed into four structural and seven non-structural proteins 
required for the replication. The structural proteins (VP1-VP4) form the characteristic 
icosahedral capsid of all members of the genus Enterovirus.20 The original assembly of these 
four viral proteins forms structural specificities which will serve as cellular binding site: a star-
shaped dome on the icosahedral 5-fold axis from five VP1 units and a depression surrounding 
the dome forming a “canyon”.21,22,23 The majority of RV-A and RV-B binds to ICAM-1, one of 
the members of the immunoglobulin superfamily, through the “canyon”24 but the pentameric 
dome of the minor group (10% of all RV-A and RV-B) has an affinity for the low-density 
lipoprotein receptor (LDL-R).25 Furthermore, it was recently reported that RV-C15 uses 
cadherin-related family member 3 (CDHR3) as its cellular receptor.26,27 Viruses of the 
Enterovirus genus, and especially RV-A and RV-B, are characterized by the presence of a 
hydrophobic cavity under the floor of the canyon. In many RVs, this cavity contains a small lipid 
molecule of cellular origin, called “pocket factor”.28 This molecule stabilizes the viral capsid and 
takes part in the capsid uncoating process during viral entry.  
The high genetic and antigenic variability across RVs hampers the development of vaccines 
and prompts researchers to develop antiviral compounds instead, by targeting conserved proteins 
like the viral protease 3C (rupintrivir),29,30 or a conserved process like viral entry (capsid 
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binders). In particular, capsid binders target the hydrophobic pocket and block virus uncoating 
and/or attachment.31,32,33,34,35 Despite forty years of extensive antiviral research, no antiviral drug 
has been approved yet for the treatment of rhinovirus infections. The best studied and now 
reference capsid binder is pleconaril (WIN 63843, 1),36 developed by Schering-Plough, for 
which clinical development for the treatment of rhinovirus infections was halted due to the poor 
in vivo activity and the rapid selection of drug-resistant variants. Two capsid binders are now in 
(pre)-clinical phase of development: vapendavir (BTA-798, 2) (Aviragen Therapeutics®, clinical 
trials phase IIb, NCT01175226) (Figure 1) and AZN001 (AstraZeneca, pre-clinical trials),37 
emphasising that research on this class of inhibitors is far from being abandoned. 
 
Figure 1. Structure of known capsid binders 1 and 2 against RVs and our chiral derivatives 3 and 
4. 
Since 2014, we have been developing a new chiral scaffold with a promising antirhinoviral 
profile against RV-B. The hit 3 (LPCRW_0005) revealed the same antiviral profile and the 
same binding pocket as pleconaril 1.38,39 Extensive pharmacomodulations were necessary to 
extend the scaffold to fill the residual electron densities observed on the “pore” side and “toe-
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end” side within this hydrophobic pocket.40 We discovered new hits, compounds 4, substituted 
with pyrazole or triazole moieties, with a potent antiviral activity against RV-B14 (Figure 2).41 
 
Figure 2. Hits 4 from “pore” side pharmacomodulations: antiviral activity against RV-B14 and 
essential ligand/protein interactions. 
Here, we carried out new heterocyclic pharmacomodulations to lengthen our scaffold on the 
closed side of the VP1 pocket. This effort led us to identify two analogues similar to 1. Their 
broad-spectrum activity (RV-A and RV-B) as well as their antiviral mechanism of action have 
been explored. Moreover, the presence of a nitro group on the cycle A led us to evaluate their in 
vitro genotoxicity using a micronucleus test. In addition, we have assessed the in vitro resistance 
emergence against RV-B14 in comparison with 1. Evaluations of the new SARs have also been 
performed based on in silico molecular docking. 
RESULTS 
Synthesis of the heterocyclic antirhinoviral library. 
The synthetic routes for all derivatives studied in this research program are described in 
Scheme 1. The 2-nitrobenzyl chloride cores 6 were prepared by means of a reduction of 
carboxylic acid with a stabilized BH3.THF solution. Then, a chlorination with SOCl2 produced 
6a-6d. 
π-stacking 
with Y197
H-bond with 
Y128
π-stacking with 
Y128/Y152
TOE-END
PORE
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The hetero-functionalization on the “pore” side was carried out using an organic electron 
donor named TDAE (Tetrakis(DimethylAmino)Ethylene). This agent generates a carbanion from 
benzyl chloride by two sequential single-electron transfer (SET).42 A nucleophilic addition on 
the C=O bond of aldehyde derivatives allows then to form the chiral secondary alcohol linker 
(Scheme 1, route c). So, pyrazole and triazolic derivatives 9c-9f were obtained from commercial 
reagents (4-(1H-pyrazol-1-yl)benzaldehyde and 4-(1H-1,2,4-triazol-1-yl)benzaldehyde) and 6a-
6c. For pyridinic analogues, we prepared upstream the aldehyde 8 from a Suzuki-Miyaura cross-
coupling reaction (Scheme 1, route d) and a TDAE strategy led us to compounds 9a and 9b. 
Finally, the brominated compounds 9b, 9c and 9f are engaged in a last pallado-catalyzed 
coupling to functionalize the "toe-end" position (Scheme 1, route e). The use of Pd(PPh3)2Cl2 as 
catalyst allowed us to prepare the pyridinic analogues 10a-10c with yields between 66 and 78%. 
The last compounds bearing a pyrazole or a triazole (10d-10j) were prepared with the high 
reactive catalyst Pd(dppf)Cl2 leading to yields up to 96%. 
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Scheme 1. General procedure for the synthesis of the heterocyclic antirhinoviral librarya 
 
a Reagents and conditions: (a) BH3.THF, THF, RT, 3 days; (b) SOCl2, Et3N, CH2Cl2, RT, 12 h, 
79-92% (2 steps); (c) 8, 4-(1H-pyrazol-1-yl)benzaldehyde or 4-(1H-1,2,4-triazol-1-
yl)benzaldehyde, TDAE, DMF, 1) -20 °C, 1 h, 2) RT, 12 h, 13-35%; (d) pyridin-4-ylboronic 
acid, Pd(PPh3)4, K2CO3, DMF/Water, MW (130 °C), 30 min, 85%; (e) boronic acid derivative, 
Pd(PPh3)2Cl2, K2CO3, dioxane, 80 °C, 12 h, 66-78% for 10a-10c or boronic acid derivative, 
Pd(dppf)Cl2, K2CO3, dioxane/water, 80 °C, 12 h, 54-96% for 10d-10j. 
Identification of antirhinoviral compounds by CPE reduction assays. 
The newly synthesized series of compounds have been evaluated for in vitro antiviral activity 
against RV-B14 in a cell-based CPE reduction assay on HeLa Rh cells. Antiviral activity is 
expressed as the concentration at which 50% of virus-induced CPE was inhibited (EC50). 
Compound cytotoxicity (CC50) was assessed in parallel in compound-treated, uninfected cells. 
Pleconaril 1 was used as a reference capsid binder. Compounds were classified according to the 
moieties inserted on the “pore” side: 4-pyridinyle, 1H-pyrazol-1-yl, or 1H-triazol-1-yl. From 
there, the antirhinoviral properties of (aza)-heterocycles as well as halogens (chlorine, bromine, 
and fluor) were studied.  
We first assessed the antiviral activity of the pyridinic analogues 9a, 9b, and 10a-10c but we 
could not detect an improvement of EC50 compared to the hits 4 (Table 1). In contrast, 
compounds bearing a pyrazole or a triazole (9c-9f and 10d-10j) on the “pore” side showed a 
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more potent antiviral activity against RV-B14 compared to 4, especially those substituted with a 
1-methyl-1H-pyrazol-4-yl towards the “toe-end” side (10e and 10h), with EC50 values of 0.2 µM 
and a SI > 1235 µM. Moreover, we found that the substitution of a trifluoromethyl group on the 
pyrazole moiety (10d and 10g) increased the EC50 values of the compounds and significantly 
affected the cytotoxicity of the respective compounds (CC50 = 14-21 µM), thereby decreasing 
their selectivity index. The dimethylisoxazol moieties (10f and 10i) induced a complete loss of 
antiviral activity against RV-B14. These observations underline the significance of steric 
hindrance on the "toe-end" side.  
In addition, brominated analogues 9c and 9f showed a similar antiviral activity but a less 
desirable SI due to a considerable anti-metabolic activity (CC50 < 39 µM). To overcome this 
toxicity, the chlorinated (9d) and fluorinated (9e) compounds have been evaluated. By providing 
fluorine and chlorine, bioisostere of bromine, the cytotoxic effects on HeLa cells were 
significantly improved (CC50 > 100). 
Altogether, these data indicate that the addition of a methylpyrazole or chlorine can improve 
the antiviral activity with negligible cell toxicity, thus improving the SI. The two most promising 
hits (10e and 10h) displayed the required characteristics for the further studies.  
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Table 1. In vitro biological activity of racemic compounds against RV-B14.a 
 
 
Entry (rac)-Compd R1 R2 
EC50 RV-B14 
(µM)b 
CC50 HeLa 
(µM)c 
SId 
1 9a 4-pyridinyl COOCH3 6.4 ± 1.1 > 264 > 41 
2 9b 4-pyridinyl Br 0.59 ± 0.01 > 250 > 424 
3 10a 4-pyridinyl 
 
1.3 ± 0.5  > 248 > 191 
4 10b 4-pyridinyl 
 
1.2 ± 0.2 > 86 > 72 
5 10c 4-pyridinyl 
 
1.0 ± 0.3 > 100 > 100 
6 9c 1H-pyrazol-1-yl Br 0.25 ± 0.06 22.5 ± 0.7 90 
7 9d 1H-pyrazol-1-yl Cl 0.128 ± 0.004 > 100 > 781 
8 9e 1H-pyrazol-1-yl F 8.7 ± 0.1 > 100 > 12 
9 10d 1H-pyrazol-1-yl 
 
0.5 ± 0.3 14 ± 12 29.4 
10 10e 1H-pyrazol-1-yl 
 
0.2 ± 0.1 > 247 > 1235 
11 10f 1H-pyrazol-1-yl 
 
> 247 14 ± 3 - 
12 9f 1H-1,2,4-triazol-1-yl Br 0.25 ± 0.07 39 ± 1 156 
13 10g 1H-1,2,4-triazol-1-yl 
 
0.4 ± 0.2 21 ± 4 52.5 
14 10h 1H-1,2,4-triazol-1-yl 
 
0.18 ± 0.05 > 256 > 1422 
15 10i 1H-1,2,4-triazol-1-yl 
 
> 247 > 256 - 
16 10j 1H-1,2,4-triazol-1-yl 
 
0.4 ± 0.2 44 ± 14 110 
17 1 pleconaril  0.03 ± 0.02 > 131 > 4039 
a All values are expressed as median ± Med. Abs. Dev. b EC50 = 50% effective concentration 
(concentration at which 50% inhibition of virus-induced cell death is observed). c CC50 = 50% 
cytotoxic concentration (concentration at which 50% adverse effect is observed on host cell 
viability). d SI = selectivity index for RV-B14, SI = CC50/EC50. (rac) = racemic. 
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Absolute configuration influence 10e and 10h pharmacological activities. 
We previously observed that enantioseparation significantly improves the activity of this class 
of compounds.41 Therefore, we proceeded to the separation and characterization of the 
enantiomers for compounds 10e and 10h, and we tested the antiviral activity of the separated 
enantiomers against RV-B14 in a cell-based CPE reduction assay. 
The two enantiomers were correctly separated according to the same methodology previously 
described.41 To determine their absolute configuration, we used again a Mosher’s protocol by 
using the enantiomers 10h followed by circular dichroisms to know the stereochemistry of the 
enantiopure compounds 10e. This detail methodology is described in the supporting information.  
Similarly to the previous series of enantioseparated compounds, we appreciated an increased 
antiviral activity and selectivity index for the (S)-enantiomers (Table 2). The fold increase of 
EC50 of these enantiopure compounds compared to the racemic mixture was more pronounced 
than that observed in the previous series.41 Despite the retained antiviral activity of the (R)-10e 
enantiomer, the (S)-configuration of compound 10e showed a gain in activity of 5.7 fold, 
whereas (S)-10h was 3 fold more active than the racemic counterpart. For the enantioseparated-
compounds, an antiviral activity similar to or higher than that of 1 was reached. In summary, we 
identified two new hit compounds equally active as pleconaril 1, in the context of in vitro RV-
B14 infection. Furthermore, we could further demonstrate that enantioseparation significantly 
improves the antiviral activity and selectivity index of this class of compounds. 
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Table 2. In vitro biological activity of enantiopure compounds against RV-B14.a 
Entry Compd 
EC50 RV-B14 
(µM)b 
CC
50
 HeLa  
(µM)c 
SId 
1 10e* 0.2 ± 0.1 > 1000 > 5000 
2 (S)-10e 0.035 ± 0.006 > 342 > 9771 
3 (R)-10e 2.5 ± 0.9 > 342 > 136 
4 10h* 0.18 ± 0.05 699 ± 63 3883 
5 (S)-10h 0.06 ± 0.03 > 342 > 5700 
6 (R)-10h > 128 > 342 - 
7 1 0.03 ± 0.02 > 131 > 4039 
a All values are expressed as median ± Med. Abs. Dev. b EC50 = 50% effective concentration 
(concentration at which 50% inhibition of virus-induced cell death is observed). c CC50 = 50% 
cytotoxic concentration (concentration at which 50% adverse effect is observed on host cell 
viability). d SI = selectivity index for RV-B14, SI = CC50/EC50. * Racemic compound. 
Pan-RV activities of 10e and 10h. 
The antiviral activity of the most promising compounds of the series, compounds 10e and 10h, 
and their enantioseparated counterparts was evaluated against a representative panel of 
rhinoviruses belonging to type A and type B: RV-A02, RV-A08, RV-A28, RV-A85, and RV-
A89 (type A) and RV-B42 and RV-B70 (type B).  
All the compounds resulted to be active against RV-group B in a similar range, with the 
exception of RV-B42 type, which is known to be naturally resistant to pleconaril-like capsid 
binders.46 Interestingly, for the first time, we could detect an antiviral activity of this class of 
compounds against A-group, in particular in the context of RV-A89 infection. Remarkably, for 
the only type A-virus sensitive to compounds 10e and 10h, the (R)-configuration was more 
active than the (S)-configuration. This switch in enantiomer activity could reflect specific 
properties of the pocket.  
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Table 3. Evaluation of pan-RV activities of the enantiomers of 10e and 10h.a 
a All values are expressed as median ± Med. Abs. Dev. b EC50 = 50% effective concentration 
(concentration at which 50% inhibition of virus-induced cell death is observed).  
10e and 10h act as early stage inhibitors of rhinovirus replication. 
To confirm the mode of action of the newly synthetized analogues, a time of addition 
experiment was performed. Compounds 10e and 10h and the most active enantioseparated 
counterparts were added at selected time points before, during, and after infection. Viral 
replication was then quantified 8 hours after infection by RT-qPCR on intracellular viral RNA. 
We observed that both the racemic mixtures of 10e and 10h and the purified enantiomers (S)-10e 
and (S)-10h interfered with RV-B14 replication at an early stage. The compounds could prevent 
virus replication only when added 2 hours prior or at the time of infection, which was reflected in 
a decreased intracellular viral RNA load at 8 hours post infection (Figure 3). The inhibitory 
effect of the molecules was lost when added 2 hours after infection (no reduction in viral RNA 
load compared to the virus control (VC)) indicating that the compounds act at an early stage of 
rhinovirus replication, similarly to 1 and the initial hit 3 (LPCRW_0005).39 These observations 
suggest that the performed pharmacomodulations did not alter the mechanism of action of this 
series of compounds. 
Types 
EC
50
 1 
(µM)b 
EC
50 
(S)-10e 
(µM)b 
EC
50 
(R)-10e 
(µM)b 
EC
50
 (S)-10h 
(µM)b 
EC
50
 (R)-10h 
(µM)b 
RV-A RV-A02 0.015 ± 0.002 > 128 > 128 > 128 > 128 
RV-A08 0.49 ± 0.09 > 128 > 128 > 128 > 128 
RV-A28 0.015 ± 0.008 > 128 > 128 > 128 > 128 
RV-A85 0.011 ± 0.002 > 128 > 128 > 128 > 128 
RV-A89 
0.0040 ± 
0.0001 
2.4 ± 0.5 
0.190 ± 0.001 
> 128 1.5 ± 0.4 
RV-B RV-B14 0.03 ± 0.02  0.035 ± 0.006 2.5 ± 0.9 0.06 ± 0.03 > 128 
RV-B42 > 128 > 128 > 128 > 128 > 128 
RV-B70 0.167 ± 0.007 0.017 ± 0.006 > 128 0.05 ± 0.03 > 20 
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Figure 3. Similar to 1, compounds 10e and 10h and their active enantiomers interfere with RV-
B14 replication at an early stage. 
Drug-resistance development is delayed in presence of compounds 10e and 10h as 
compared with pleconaril 1. 
The rapid development of resistance against capsid binders is a major burden both in vitro and 
in vivo, as demonstrated by several clinical trials. To evaluate the dynamics of resistance 
emergence, RV-B14 was passaged in the presence of 10e, 10h and 1 at their in vitro EC50, 
2xEC50 and 4xEC50 (Table 4). In the sub-optimal concentration (in vitro EC50), the three 
compounds developed resistance by passage 3, with 10e-treated cultures being less prone to 
develop resistance by passage 4 (only 50% of infected-treated cultures showed viral-induced 
CPE). However, at the higher concentration of 2xEC50 and 4xEC50, which correspond to an 
efficacious antiviral treatment, resistance development was more rapid in 1-treated than in 10e- 
and 10h-treated cultures. Although it is difficult to ultimately conclude on in vitro evolutionary 
experiments, these data may suggest that RV-B14 is less prone to develop resistance in presence 
of compound 10e or 10h compared to 1. 
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Table 4. RV-B14 induced CPE at passage 1-4 (P1-4) in the presence of compounds 10e, 10h, or 
1. 
Compd xEC50 P1a P2a P3a P4a 
 
10e 
 
4 0% 0% 0% 0% 
2 0% 0% 0% 50% 
1 0% 0% 50% 50% 
10h 
4 0% 0% 0% 0% 
2 0% 0% 25% 50% 
1 0% 50% 75% 100% 
1 
4 0% 0% 25% 25% 
2 0% 0% 100% 100% 
1 0% 100% 100% 100% 
VC  100% 100% 100% 100% 
aPercentage of wells showing full CPE (n=4). VC: virus control. 
 
Next, in order to correlate the resistant phenotype to eventual drug-resistant virus variants, the 
VP1 genomic region from the cultures treated with compound 10e and 10h at passage 4 was 
analyzed by sequencing. Virus harvested from cultures that proofed to be equally sensitive to the 
compound after four passages and that did not show any sign of viral-induced CPE, did not show 
any mutations except for four (out of 14) cultures that carried either the amino acid A150V or 
V191E. Both mutations have been associated with in vitro resistance to 1.43 On the other hand, 
the virus harvested from drug-resistant cultures carried one of the mutations A150V, C199W, or 
N105S. As mentioned before, the A150V but also the position C199 (C199Y variant) was 
previously described for in vitro resistance to 1.44 The N105S substitution is a novel variant 
associated to 10h resistance. 
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Table 5. Mutations detected in the VP1 gene of RV-B14 cultures 1-4 (C1-C4) after 4 passages in 
the presence of compounds 10e or 10h. 
Compd xEC50 C1 C2 C3 C4 
10e 
4 A150V A150V - - 
2 A150V A150V V191E - 
1 C199W C199W - - 
10h 
4 A150V - - - 
2 N105S N105S - - 
1 C199W C199W C199W C199W 
Green: no CPE. Red: full CPE. 
In vitro genotoxicity study. 
The presence of a nitro group led us to evaluate the potential clastogenic and/or aneugenic 
activities of the most active enantiomers (S)-10e and (S)-10h. Indeed, the nitroaromatics can be 
reduced in vivo to form several reactive intermediates (nitro radical, nitroso, nitroxyl radical, or 
aromatic N-oxide). In this research, their genotoxic effects were evaluated using an in vitro 
micronucleus clastogenicity study.45 This essay detects compounds that damage chromosomes or 
interfere with the cell division apparatus, to produce abnormal DNA fragments. It is currently a 
prerequisite for future drug development, especially in the framework of research on nitro 
compounds. 
The test is conducted by incubating CHO cells in culture with the test compounds at increasing 
concentrations (1 µM to 100 µM), with and without metabolic activation. After exposure, the 
cells are cultured for a period of time allowing the formation of micronuclei in interphase 
daughter cells in the presence of a blocking agent of cytokinesis (cytochalasin B). The harvested 
cells in interphase are subjected to specific staining and analysis for the presence of micronuclei.  
All results are presented in Tables A and B (Supporting information). No significant increase 
in micronucleated cell rates was observed for all the non-cytotoxic concentrations, in either the 
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absence or presence of the metabolizing mixture. These data indicated that the compounds (S)-
10e and (S)-10h did not exert cytogenetic effects in CHO cells in culture, and did not produce 
metabolites with cytogenetic effects. As a conclusion, these capsid binders gave negative results 
in the in vitro micronucleus assay, indicating that they devoid of clastogenic and/or aneugenic 
activities in these experimental conditions. 
Molecular modelling. 
The reported derivatives were studied by docking experiments to gain insight into the 
compounds binding mode. The binding pocket was fixed at the capsid site and the computation 
were carried out by a previously reported procedure.40 The analyses of the Plants proposed 
binding poses showed that the compounds shared a consistent binding mode, superimposable 
with the one of the reference compounds 3 and 4a (Figure 5).  
 
  
Figure 5. Plants proposed binding mode for compounds (left panel) 9b (white), 9c (orange), and 
9f (cyan); and (right panel) 10c (cyan), 10d (white), and 10g (orange). References compounds, 3 
magenta, and 4a grey, were also reported as lines. Residues involved in contacts were depicted 
as green lines. VP1 protein is reported as yellow cartoon. H-bonds are showed as yellow dot 
lines. 
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The binding mode analyses led us to highlight some key interactions: (a) the nitro-phenyl 
moiety had π-π staking with Y152, (b) the linker oxygen atom formed an H-bond with Y128 side 
chain, and (c) the unsubstituted phenyl ring had hydrophobic interactions with L106, V191 and 
M221 side chains. The pore side substituents (pyridine, pyrazole, and triazole) were involved in 
π-π staking contact with Y197. The toe-end substituents had to be divided in two groups: the 
aromatic groups formed staking contact with F186 (Figure 5, right panel); whereas the halogen 
atoms established steric rather than electrostatic interactions at the hydrophobic pocket mainly 
formed by Y152, F186, and M224 (Figure 5, left panel). More in detail, by comparing the 
compounds 10d, 10e, and 10f, we observed that the dimethylisoxazole moiety led to an unrelated 
binding mode, while the CF3 (10d) and the CH3 (10e) groups were superimposable and had 
hydrophobic contacts with I130, A150, and V176 (Figure D, Supporting information). 
We also studied the binding modes of the 10e and 10h enantiomers. The docking poses 
showed a main difference between the (R) and (S) couples. The (S)-enantiomers were in the right 
geometry to form an H-bond between the chiral oxygen alcohol atom and the Y128 side chain; 
on the contrary, for (R)-enantiomers the alcohol group pointed toward the hydrophobic residue 
V191 destabilizing the binding (Figure 6). This was in accordance with the biological data and 
consistent with the already reported docking poses.41 
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Figure 6. Plants proposed binding mode for derivatives (R)-10e (orange) and (S)-10e (cyan). 
Residues involved in contacts were depicted as green lines. VP1 protein is reported as yellow 
cartoon. H-bond is showed as yellow dot line. 
The capsid binder compounds integrate into a highly conserved pocket mainly formed by 
VP1.46 The serotypes VP1 primary sequence conservation was studied in order to clarify the 
broad range susceptibility of the 10e and 10h compounds. The analyses were focused on the 
residues directly involved in interactions with studied compounds. 
For the RV-B studied isotypes (Table 4), the comparison between RV-B14 and RV-B70 
isotypes highlighted that only the M224 changed to isoleucine. This residue had a role in the 
stabilization of studied compounds doing contacts with the toe-end substituents. Nevertheless, 
this residue change did not affect the contact and the binding mode (data not shown). Actually, 
the more hydrophobic nature of the isoleucine might strengthen the interaction with the pyrazole 
ring. The comparison between the RV-B14 and RV-B42 highlighted two residues change: Y152 
to Phe and V191 to Leu. The pattern F152/L191 was already described as “diagnostic” for 
resistance to capsid binder.46, 46 In particular, the bulkier leucine instead of valine might have a 
detrimental steric effect in the compounds binding. This hypothesis was confirmed by docking 
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studies at the homology model for the RV-B42 VP1. The docking experiments for 10e and 10h 
led to an unrelated binding mode (data not shown). 
 
Table 4. VP1 alignment of the amino acids of RV-B types in the binding pocket. 
 Amino acid position 
RV-B 102 104 106 116 124 126 128 150 151 152 174 175 176 186 188 191 197 198 219 221 224 245 
14 W I L L F S Y A M Y P S V F V V Y N N M M H 
42 - - - - - - - - - F - - - - - L - - - - - - 
70 - - - - - - - - - - - - - - - - - - - - I - 
 
We also analysed the VP1 sequence for the RV-A studied isotypes (Table 5). Our aim was to 
rationalize the important inhibitory activity of 10e and 10h at the A89 isotype. Worthy, the 
valine 98 was peculiar for A89 isotype, and this residue was in the central part of the canyon. 
The docking experiments at the RV-A89 VP1 homology model confirmed the role of V98. 
Indeed, the smaller valine instead of an isoleucine, which featured the other studied isotypes, 
created a small space filled by the inhibitors nitro group. This binding mode was also featured 
by: (a) an aromatic contact between the pore side pyrazole and Y190; (b) a hydrophobic 
interaction between the toe-end pyrazole and F179 and I217; and (c) the nitro-phenyl group 
formed contact with Y144 and I181. Worthily, the reported binding mode showed only for the 
(R)-enantiomers an H-bond with the S120 side chain (Figure 7).  
Table 5. VP1 alignment of the amino acids of RV-A types in the binding pocket. 
 Amino acid position 
RV-A 77 96 98 100 118 120 122 124 142 143 144 166 167 168 179 181 184 190 212 214 217 238 
89 I W V L F S I I F M Y A S V F I M Y N M I H 
2 - - I - - - - L Y - - - - - - L L - - - L - 
8 - - I I - - - - I - - - - - - - S - - - - L 
28 - - I - - - - - - - - - - - - - - -  - L - 
85 - - I I - - - L Y - - - - - - - - - - - L - 
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Figure 7. Proposed binding mode for the compounds (R)-10e (cyan) and (S)-10e (orange) at RV-
A89 isotype. Residues of RV-A2 are reported as green line; residues of RV-A89 are reported as 
grey lines. The cartoon of A89 isotype is also reported. H-bond is showed as yellow dot line. 
The docking studies provided us a general binding mode able to fit the biological activity. 
Nevertheless, several other factors might be involved in the compounds binding such as: the 
effect of other changed amino acids, the residues outside the binding pocket and the compounds 
accessibility to the pocket. 
DISCUSSION 
Capsid binders are still considered attractive molecules for the prophylaxis and treatment of 
rhino/enterovirus infections, as witnessed by the abundancy of studies/clinical trials over the 
recent years. These molecules target the hydrophobic pocket beneath the floor of the canyon 
formed by approximately twenty amino acids of VP1. This viral protein is highly variable across 
rhinoviruses and enteroviruses and so is the composition of the pocket. It is hence a challenge to 
design molecules that are at the same time strong capsid binders and pan-genotype active. Here, 
we describe the chemical modulation of a pleconaril-like capsid binder with an equal in vitro 
antiviral activity as pleconaril 1 and an expanding spectrum of activity across rhinoviruses.  
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We report, for the first time since we have been working with the compound 4 backbone, an 
analogue with a comparable in vitro antiviral potency as 1. Indeed, following enantioseparation, 
(S)-10h showed an equal potency in the context of RV-B14 infection and an even higher potency 
than 1 after RV-B70 infection. In addition, both 10e and 10h new hits exhibited a delayed in 
vitro resistance development when compared with 1. Although the interpretation of in vitro 
evolutionary experiments is challenging, our data suggest that RV-B14 is less prone to develop 
resistance in presence of compound 10e and 10h compared to 1. As resistance development has 
been a major problem during the clinical development phase of 1, our data on this novel class of 
pleconaril-like compounds are highly encouraging. Moreover, we correlated the resistance 
phenotype with mutations in VP1. Two of the altered positions (A150 and C199) were 
previously associated with resistance to 1, whereas N105S is a newly identified variant 
specifically associated with compound 10h and/or 10e. These residues lay in close proximity 
with the residues defining the hydrophobic pocket, suggesting that the environment around the 
pocket is also crucial for compound-binding.  
This study also shed light on the dynamics of interaction of the newly synthetized x-analogues 
with the binding pocket by means of molecular docking simulations. We could identify the 
residue V98 in RV-A as a key residue associated with in vitro antiviral activity. In addition, we 
could explain the different enantiomer preference in the context of RV-B or RV-A89 infection. 
Only the (R)-enantiomer could engage in an H-bond with the pocket residue S120, suggesting 
that this residue is also crucial for antiviral activity. Altogether these data will guide the synthesis 
of more potent and broad-spectrum compounds.   
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CONCLUSION 
In summary, we identified a novel anti-RV inhibitors series with a promising pharmacological 
profile. Several compounds displayed sub-micromolar EC50 values against a representative panel 
RV species. Following our previous work, we undertook this SAR study in order to lengthen our 
scaffold on the closed side of the hydrophobic pocket, called the "toe-end". With this we have 
confirmed the interest of hydrophobic interactions with the residues I130, A150, and V176 of 
“toe-end” side. Several pharmacophores have been identified with in particular a methyl 
pyrazole inducing numerous hydrophobic interactions within the pocket. Among the novel 
compounds investigated, the enantiopure compounds 10e and 10h were found to inhibit 
replication of RV-A and RV-B species with an EC50 between 0.017 and 0.19 µM against RV-
B14, RV-B70 and RV-A89 respectively, which is comparable to 1. A determination of the 
absolute configuration by a Mosher protocol validated the importance of the (S)-alcohol linker 
against RV-B14 and RV-B70. Conversely, the (R)-stereocenter of 10e induces activity against 
RV-A89. The docking study showed that an H-bond with S120 is the key to this activity. 
The results of time-of-addition experiments, in which (S)-10e and (S)-10h showed a similar 
inhibition profile with that of 1 against RV-B14, and a resistant development study, implied that 
10 act at the early stage of the viral infection. In addition, a new point mutation N105S on the 
viral capsid protein was identified. In vitro genotoxicity study also displayed that 10 have no 
clastogenic and/or aneugenic activities in CHO cells despite the nitro group. In conclusion, these 
complete studies led us to identify two potent antivirals with a broad-spectrum activity against 
RV-A and RV-B species. In view of the promising pharmacological properties, we thus will 
explore the pan-EV potential of these new pyrazolic inhibitors.  
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EXPERIMENTAL SECTION 
Chemistry.  
General methods. Commercially available reagents and solvents were used without further 
purification. Reactions were monitored by thin-layer chromatography (plates coated with silica 
gel 60 F254 from Merck) and by LC-MS analyses with a Thermo Scientific Accela High Speed 
LC System® coupled with a single quadrupole mass spectrometer Thermo MSQ Plus®. The RP-
HPLC column used is a Thermo Hypersil Gold® 50 x 2.1 mm (C18 bounded), with particles of 
1.9 µm diameter. Analysis was 8 min running with a MeOH/H2O eluent gradient from 50:50 to 
95:05. Silica gel 60 (70-230 mesh from Macherey-Nagel) was used for flash chromatography. 
Melting points were measured in open capillary tubes with Büchi apparatus and are uncorrected. 
1H and 13C NMR spectra were recorded at room temperature in deuterated solvents on a Brüker 
Avance-250 instrument (250 MHz), a Brüker Avance III nanobay-300 MHz or a Brüker Avance 
III nanobay-400 MHz. Chemical shifts (δ) are reported in parts per million (ppm) relative to 
TMS as internal standard or relative to the solvent [1H: δ(DMSO) = 2.50 ppm, δ(CDCl3) = 7.26 
ppm; 13C: δ(DMSO) = 39.52 ppm, δ(CDCl3) = 77.16 ppm]. Data are reported as follows: 
chemical shift, multiplicity (s = singulet, d = doublet, t = triplet, q = quartet, dd = doublet of 
doublets, m = multiplet, and bs = broad singlet), coupling constant in Hertz, and integration. 
Two-dimensional spectroscopy (HSQC and HMBC) was used to assist in the assignment and the 
data are not reported. Accurate mass measurements (HRMS) were recorded on a TOF 
spectrometer, realized by Spectropôle of Faculté des Sciences de Saint Jérôme, Marseille 
(France). Purity of tested compounds was found to be > 95% by high pressure liquid 
chromatography (HPLC). 
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4-Bromo-1-(chloromethyl)-2-nitrobenzene (6a). Step 1: BH3 (1.0 M solution in THF, 7 mL, 7 
mmol) was slowly added to a solution of 4-bromo-2-nitrobenzoic acid (2 g, 8.1 mmol) in 
anhydrous THF (10 mL) at 0 °C. The mixture was stirred at room temperature for 3 days. The 
mixture was quenched by dropwise addition of a saturated aqueous solution of NaHCO3. Then, 
the mixture was extracted with EtOAc. The combined organic layers were washed with water 
and brine, dried over Na2SO4, filtered off and concentrated under reduced pressure to afford the 
pure (4-bromo-2-nitrophenyl)methanol (1.3 g, 5.7 mmol, 71 %) as a beige solid. Step 2: To a 
solution of (4-bromo-2-nitrophenyl)methanol (1.3 g, 5.7 mmol) in CH2Cl2 (10 mL) was added a 
few drops of triethylamine, and SOCl2 (0.5 mL, 6.7 mmol) at 0 °C. After stirring overnight at 
room temperature, the reaction was quenched by addition of a aqueous solution NaOH 2N. The 
mixture was washed with water and brine, dried over Na2SO4, filtered off and concentrated under 
reduced pressure. After purification by column chromatography on silica gel (Petroleum 
ether/EtOAc 8:2), the pure product 6a (1,3 g, 5,2 mmol, 92%) was obtained as a beige solid. 1H 
NMR (250 MHz, CDCl3) δ 8.21 (d, J = 1.7 Hz, 1H), 7.77 (dd, J = 8.3, 1.7 Hz, 1H). 7.59 (d, J = 
8.3 Hz, 1H), 4.93 (s, 2H, CH2). 
13C NMR (62.5 MHz, CDCl3) δ 148.4 (CIV,Ar), 136.9 (CHAr), 
133.0 (CHAr), 131.6 (CIV,Ar), 128.4 (CHAr), 122.8 (CIV,Ar), 42.3 (CH2). 
4-Chloro-1-(chloromethyl)-2-nitrobenzene (6b). Following the same procedure used to 
prepare 6a, the crude product was prepared with 4-chloro-2-nitrobenzoic acid (2.3 g, 11.4 
mmol). After purification by column chromatography on silica gel (CH2Cl2), the pure product 6b 
(2.14 g, 10.4 mmol, 92%) was obtained as brown oil. 1H NMR (250 MHz, CDCl3) δ 8.00 (d, J = 
1.6 Hz, 1H), 7,65-7,57 (m, 2H), 4,91 (s, 2H, CH2). 
13C NMR (62.5 MHz, CDCl3) δ 148,2 
(CIV,Ar), 135,3 (CIV,Ar), 133,8 (CHAr), 132,8 (CHAr), 131,0 (CIV,Ar), 125,4 (CHAr), 42,2 (CH2).  
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4-Fluoro-1-(chloromethyl)-2-nitrobenzene (6c). Following the same procedure used to prepare 
6a, the crude product was prepared with 4-fluoro-2-nitrobenzoic acid (1.3 g, 7.0 mmol). After 
purification by column chromatography on silica gel (CH2Cl2), the pure product 6c (1.16 g, 6.1 
mmol, 89%) was obtained as green oil. 1H NMR (250 MHz, CDCl3) δ 7,75 (dd, JHF = 8.2 Hz, 
JHH = 2.7 Hz, 1H), 7,68 (dd, JHH = 8.6 Hz, JHF = 5.4 Hz, 1H), 7,40-7,33 (m, 1H), 4,91 (s, 2H, 
CH2). 
13C NMR (62.5 MHz, CDCl3) δ 161.9 (d, 
1JCF = 251 Hz, CIV,Ar), 148.4 (d, 
3JCF =8 Hz, 
CIV,Ar), 133.5 (d, 
3JCF = 8 Hz, CHAr), 128.6 (d, 
4JCF = 4 Hz, CIV,Ar), 121.1 (d, 
2JCF = 21 Hz, CHAr), 
113.0 (d, 2JCF = 27 Hz, CHAr), 42.2 (CH2). 
Methyl 4-(chloromethyl)-3-nitrobenzoate (6d). Following the same procedure used to prepare 
6a, 4-(methoxycarbonyl)-2-nitrobenzoic acid (1.0 g, 4.4 mmol) was used to obtain the pure 
product 6d (903 mg, 3.9 mmol, 79%) as brown oil. 1H NMR (250 MHz, CDCl3) δ 8.61 (d, J = 
1.7 Hz, 1H), 8.24 (dd, J = 8.0, 1.7 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 4.97 (s, 2H, CH2), 3.95 (s, 
3H, CH3). 
13C NMR (62.5 MHz, CDCl3) δ 164.5 (C=O), 147.9 (CIV,Ar), 136.7 (CIV,Ar), 134.2 
(CHAr), 131.9 (CHAr), 131.6 (CIV,Ar), 126.2 (CHAr), 52.9 (CH3), 42.4 (CH2). 
General procedure A for the synthesis of 9. To a glass vessel suitable for sealing with Teflon 
cap (for microwave vials) were added the benzyl chloride derivative 6a-6d (1 equiv.) and 
benzaldehyde derivative (3 equiv.). The vessel was capped and then evacuated and backfilled 
with N2 (thrice-repeated process). Anhydrous DMF (3.5 mL/mmol) was introduced and the 
solution was vigorously stirred for 20 min at -20 °C. TDAE (1.06 equiv.) was added slowly and 
the mixture was stirred for one hour. Then, the reaction was stirred at room temperature 
overnight. After LC-MS analysis clearly showed that the chloride had been totally consumed, the 
reaction was hydrolyzed with water. The mixture was then extracted with ethyl acetate. The 
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combined organic layers were washed with water and brine, dried over Na2SO4, filtered off, and 
concentrated under reduced pressure to afford the corresponding crude product. 
Methyl 4-(2-hydroxy-2-(4-(pyridin-4-yl)phenyl)ethyl)-3-nitrobenzoate (9a). The crude 
product was prepared according to procedure A starting from 6d (100 mg, 0.43 mmol) and 8 
(239 mg, 1.30 mmol). After purification by column chromatography on silica gel 
(CH2Cl2/Diethyl ether 9:1 to 6:4), the pure product 9a (64 mg, 0.17 mmol, 39%) was obtained as 
yellow solid. m.p: 188 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.62 (d, J = 6.1 Hz, 2H), 8.37 (d, J 
= 1.6 Hz, 1H), 8.15 (dd, J = 8.1, 1.6 Hz, 1H), 7.79 (d, J = 8.2 Hz, 2H), 7.71 (d, J = 6.1 Hz, 2H), 
7.67 (d, J = 8.1 Hz, 1H), 7.47 (d, J = 8.2 Hz,2H), 5.59 (d, J = 4.7 Hz, 1H, OH), 4.88-4.84 (m, 
1H), 3.90 (s, 3H, CH3), 3.31-3.24 (m, 2H). 
13C NMR (100 MHz, DMSO-d6) δ 164.6 (C=O), 
150.2 (2xCHAr), 150.0 (CIV,Ar), 146.7 (CIV,Ar), 146.2 (CIV,Ar), 138.4 (CHAr), 135.8 (CIV,Ar), 134.2 
(CIV,Ar), 132.4 (CHAr), 129.0 (CIV,Ar), 126.6 (2xCHAr), 126.4 (2xCHAr), 124.6 (CHAr), 121.0 
(2xCHAr), 72.0 (CH), 52.6 (CH3), 41.6 (CH2). HRMS (ESI+) m/z Calc. for C21H18N2O5 [M+H]
+ 
379.1288, found 379.1288. 
2-(4-Bromo-2-nitrophenyl)-1-(4-(pyridin-4-yl)phenyl)ethanol (9b). The crude product was 
prepared according to procedure A starting from 6a (500 mg, 1.99 mmol) and 8 (1097 mg, 5.98 
mmol). After purification by column chromatography on silica gel (EtOAc/Cyclohexane 6:4 to 
7:3), the pure product 9b (215 mg, 0.54 mmol, 27%) was obtained as light yellow solid. m.p: 177 
°C. 1H NMR (300 MHz, DMSO-d6) δ 8.62 (d, J = 5.8 Hz, 2H), 8.11 (d, J = 1.8 Hz, 1H), 7.82 
(dd, J = 8.3, 1.8 Hz, 1H), 7.78 (d, J = 8.1 Hz, 2H), 7.70 (d, J = 5.8 Hz, 2H), 7.46 (d, J = 8.3 Hz, 
1H), 7.45 (d, J = 8.1 Hz, 2H), 5.53 (d, J = 4.7 Hz, 1H, OH), 4.84-4.78 (m, 1H), 3,23-3,10 (m, 
2H). 13C NMR (75 MHz, DMSO-d6) δ 150.7 (CIV,Ar), 150.2 (2xCHAr), 146.7 (CIV,Ar), 146.2 
(CIV,Ar), 135.8 (CIV,Ar), 135.2 (CHAr), 135.1 (CIV,Ar), 132.3 (CIV,Ar), 126.6  (2xCHAr), 126.5 
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(CIV,Ar), 126.4 (2xCHAr), 121.0 (2xCHAr), 119.3 (CHAr), 71.9 (CHAr), 40.9 (CH2). HRMS (ESI+) 
m/z Calc. for C19H15BrN2O3 [M+H]
+ 399.0339, found 399.0339. 
1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(4-bromo-2-nitrophenyl)ethanol (9c). The crude product 
was prepared according to procedure A starting from 6a (500 mg, 1.99 mmol) and 4-(1H-
pyrazol-1-yl)benzaldehyde (1031 mg, 5.98 mmol). After purification by column chromatography 
on silica gel (Petroleum ether/EtOAc 7:3), the pure product 9c (230 mg, 0.59 mmol, 30%) was 
obtained as light orange solid. m.p: 164 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.47 (d, J = 2.6 
Hz, 1H), 8.10 (d, J = 2.0 Hz, 1H), 7.82 (dd, J = 8.3, 2.0 Hz, 1H), 7.79 (d, J = 8.6 Hz, 2H), 7.73 
(d, J = 1.5 Hz, 1H), 7.42 (d, J = 8.3 Hz, 1H), 7.41 (d, J = 8.6 Hz, 2H), 6.53 (dd, J = 2.6, 1.5 Hz, 
1H), 5.54 (d, J = 4,6 Hz, 1H, OH), 4.80-4.76 (m, 1H), 3.17-3.15 (m, 2H). 13C NMR (100 MHz, 
DMSO-d6) δ 150.7 (CIV,Ar), 142.8 (CIV,Ar), 140.8 (CHAr), 138.7 (CIV,Ar), 135.2 (CIV,Ar), 135.1 
(CHAr), 132.3 (CHAr), 127.6 (CHAr), 126.7 (2xCHAr), 126.5 (CIV,Ar), 119.4 (CHAr), 118.0 
(2xCHAr), 107.7 (CHAr), 71.8 (CH), 40.1 (CH2). HRMS (ESI+) m/z Calc. for C17H14BrN3O3 
[M+H]+ 388.0291, found 388.0294. 
1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(4-chloro-2-nitrophenyl)ethanol (9d). The crude product 
was prepared according to procedure A starting from 6b (200 mg, 0.97 mmol) and 4-(1H-
pyrazol-1-yl)benzaldehyde (251 mg, 1.45 mmol, 1.5 equiv.). After purification by column 
chromatography on silica gel (Petroleum ether/EtOAc 8:2 to 5:5), the pure product 9d (68 mg, 
0.19 mmol, 20%) was obtained as light yellow solid. m.p: 167 °C. 1H NMR (250 MHz, DMSO-
d6) δ 8.48 (d, J = 2.4 Hz, 1H), 8.01 (d, J = 2.2 Hz, 1H), 7.79 (d, J = 8.4 Hz, 1H), 7.73 (d, J = 8.6 
Hz, 2H), 7.69 (d, J = 2.2 Hz, 1H), 7.47 (d, J = 8.4 Hz, 1H), 7.38 (d, J = 8.6 Hz, 2H), 6.54 (dd, J = 
2.4, 2.2 Hz, 1H), 5.56 (d, J = 4.5 Hz, 1H, OH), 4.82-4.75 (m, 1H), 3.22-3.17 (m, 2H). 13C NMR 
(75 MHz, DMSO-d6) δ 150.5 (CIV,Ar), 142.8 (CIV,Ar), 140.7 (CHAr), 138.6 (CIV,Ar), 134.9 (CHAr), 
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132.3 (CIV,Ar), 131.9 (CHAr), 131.5 (CIV,Ar), 127.5 (CHAr), 126.7 (2xCHAr), 123.7 (CHAr), 118.0 
(2xCHAr), 107.6 (CHAr), 71.8 (CH), 40.9 (CH2). HRMS (ESI+) m/z Calc. for C17H14ClN3O3 
[M+H]+ 344.0796, found 344.0795. 
1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(4-fluoro-2-nitrophenyl)ethanol (9e). The crude product was 
prepared according to procedure A starting from 6c (200 mg, 1.05 mmol) and 4-(1H-pyrazol-1-
yl)benzaldehyde (273 mg, 1.58 mmol, 1.5 equiv.). After purification by column chromatography 
on silica gel (Petroleum ether/EtOAc 8:2 to 5:5), the pure product 9e (120 mg, 0.36 mmol, 35%) 
was obtained as light yellow solid. m.p: 145 °C. 1H NMR (250 MHz, DMSO-d6) δ 8.48 (d, J = 
2.3 Hz, 1H), 7.85 (dd, J = 8.9, 2.4 Hz, 1H), 7.79 (d, J = 8.5 Hz, 2H), 7.73 (d, J = 1.5 Hz, 1H), 
7.58-7.46 (m, 2H), 7.39 (d, J = 8.5 Hz, 2H), 6.53 (dd, J = 2.3, 1.5 Hz, 1H), 5.53 (d, J = 4.6 Hz, 
1H, OH), 4.81-4.74 (m, 1H), 3.19-3.17 (m, 2H). 13C NMR (62.5 MHz, DMSO-d6) δ 159.9 (d, 
1JCF = 245 Hz, CIV,Ar), 150.4 (d, 
3JCF = 8 Hz, CIV,Ar), 143.0 (CIV,Ar), 140.8 (CHAr), 138.7 (CIV,Ar), 
135.2 (d, 3JCF = 8 Hz, CHAr), 129.3 (d, 
4JCF = 4 Hz, CIV,Ar), 127.6 (CHAr), 126.7 (2xCHAr), 119.8 
(d, 2JCF = 21 Hz, CHAr), 118.0 (2xCHAr), 111.5 (d, 
2JCF = 26 Hz, CHAr), 107.8 (CHAr), 72.0 (CH), 
40.9 (CH2). HRMS (ESI+) m/z Calc. for C17H14FN3O3 [M+H]
+ 328.1092, found 328.1090. 
1-(4-(1H-1,2,4-Triazol-1-yl)phenyl)-2-(4-bromo-2-nitrophenyl)ethanol (9f). The crude 
product was prepared according to procedure A starting from 6a (500 mg, 1.99 mmol) and 4-
(1H-1,2,4-triazol-1-yl)benzaldehyde (1037 mg, 5.98 mmol). After purification by column 
chromatography on silica gel (EtOAc/Petroleum ether 8:2), the pure product 9f (101 mg, 0.26 
mmol, 13%) was obtained as yellow solid. m.p: 192 °C. 1H NMR (250 MHz, DMSO-d6) δ 9.29 
(s, 1H), 8.23 (s, 1H), 8.11 (d, J = 2,1 Hz, 1H), 7.83 (dd, J = 8.3, 2.1 Hz, 1H), 7.82 (d, J = 8.6 Hz, 
2H), 7.47 (d, J = 8.6 Hz, 2H), 7,42 (d, J = 8.3 Hz, 1H), 5,61 (d, J = 4.7 Hz, 1H, OH), 4.84-4.77 
(m, 1H), 3.18-3.15 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ 152.3 (CHAr), 150.7 (CIV,Ar), 
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144.6 (CHAr), 142.2 (CIV,Ar), 135.6 (CIV,Ar), 135.2 (CIV,Ar), 135.1 (CHAr), 132.2 (CHAr), 126.9 
(2xCHAr), 126.5 (CIV,Ar), 119.4 (CHAr), 119.1 (2xCHAr), 71.7 (CH), 40.9 (CH2). HRMS (ESI+) 
m/z Calc. for C16H13BrN4O3 [M+H]
+ 389.0244, found 389.0242. 
General procedure B for the synthesis of 10a-10c. In a sealed glass vial were introduced the 
brominated derivative (1 equiv.), boronic acid derivative (2 equiv.), Pd(PPh3)2Cl2 (3 mol%), and 
K2CO3 (2 equiv.). The vessel was capped and then, evacuated and backfilled with N2 (process 
repeated 3X). The dioxane (8 mL/mmol) was introduced and the solution was heated at 80 °C 
overnight. After cooling, the mixture was extracted with ethyl acetate. The combined organic 
layers were washed with water and brine, dried over Na2SO4, filtered off, and concentrated under 
reduced pressure to afford the corresponding crude product 10a-10c. 
2-(2-Nitro-4-(thiophen-2-yl)phenyl)-1-(4-(pyridin-4-yl)phenyl)ethanol (10a). The crude 
product was prepared according to procedure B starting from 9b (80 mg, 0.20 mmol) and 
thiophen-2-ylboronic acid (52 mg, 0.40 mmol). After purification by column chromatography on 
silica gel (Petroleum ether/EtOAc 7:3), the pure product 10a (53 mg, 0.13 mmol, 66%) was 
obtained as light yellow solid. m.p: 217 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.62 (d, J = 3.4 
Hz, 2H), 8.13 (s, 1H), 7.90-7.64 (m, 7H), 7.53-7.46 (m, 3H), 7.19-7.17 (m, 1H), 5.53 (d, J = 4.9 
Hz, 1H, OH), 4.89-4.79 (m, 1H), 3.26-3.13 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 150.6 
(CIV,Ar), 150.2 (2xCHAr), 146.7 (CIV,Ar), 146.4 (CIV,Ar), 140.6 (CHAr), 135.7 (CIV,Ar), 134.1 
(CIV,Ar), 133.2 (CHAr), 131.8 (CIV,Ar), 128.9 (CIV,Ar), 128.7 (CHAr), 126.9 (CHAr), 126.5 
(2xCHAr), 126.4 (2xCHAr), 125.3 (CHAr), 121.0 (2xCHAr), 120.2 (CHAr), 72.1 (CH), 41.3 (CH2). 
HRMS (ESI+) m/z Calc. for C23H18N2O3S [M+H]
+ 403.1111, found 403.1105. 
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2-(4-(Furan-2-yl)-2-nitrophenyl)-1-(4-(pyridin-4-yl)phenyl)ethanol (10b). The crude product 
was prepared according to procedure B starting from 9b (80 mg, 0.20 mmol) and furan-2-
ylboronic acid (45 mg, 0.40 mmol). After purification by column chromatography on silica gel 
(Petroleum ether/EtOAc 7:3), the pure product 10b (56 mg, 0.14 mmol, 73%) was obtained as 
orange solid. m.p: 219 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.62 (d, J = 5.7 Hz, 2H), 8.15 (d, J 
= 1.5 Hz, 1H), 7.91 (dd, J = 8.0, 1.5 Hz, 1H), 7,81 (d, J = 1.7 Hz, 1H), 7.78 (d, J = 8.1 Hz, 2H), 
7.70 (d, J = 5.7 Hz, 2H), 7.52 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 8.1 Hz, 2H), 7.14 (d, J = 3.2 Hz, 
1H), 6.65 (dd, J = 3.2, 1.7 Hz, 1H), 5.53 (d, J = 4,7 Hz, 1H, OH), 4,88-4,82 (m, 1H), 3.27-3.15 
(m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 150.8 (CIV,Ar), 150.5 (CIV,Ar), 150.2 (2xCHAr), 146.7 
(CIV,Ar), 146.4 (CIV,Ar), 143.8 (CHAr), 135.7 (CIV,Ar), 134.0 (CIV,Ar), 131.6 (CHAr), 129.6 (CHAr), 
126.8 (CIV,Ar), 126.5 (2xCHAr), 126.4 (2xCHAr), 121.0 (2xCHAr), 118.4 (CHAr), 112.3 (CHAr), 
107.8 (CHAr), 72.1 (CH), 41.3 (CH2). HRMS (ESI+) m/z Calc. for C23H18N2O4 [M+H]
+ 
387.1339, found 387.1338. 
2-(4-(1-Methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-2-nitrophenyl)-1-(4-(pyridin-4-
yl)phenyl)ethanol (10c). The crude product was prepared according to procedure B starting 
from 9b (80 mg, 0.20 mmol) and (1-methyl-3-trifluoromethyl-1H-pyrazol-5-yl)boronic acid (78 
mg, 0,40 mmol). After purification by column chromatography on silica gel (Petroleum 
ether/EtOAc 5:5), the pure product 10c (73 mg, 0.16 mmol, 78%)  was obtained as yellow solid. 
m.p: 151 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.63 (d, J = 4.8 Hz, 2H), 8.14 (s, 1H), 7.87 (d, J 
= 7.5 Hz, 1H), 7.80 (d, J = 7.9 Hz, 2H), 7.72-7.67 (m, 3H), 7.51 (d, J = 7.9 Hz, 2H), 7.06 (s, 1H), 
5.57 (d, J = 4.5 Hz, 1H, OH), 4.89-4.87 (m, 1H), 3.97 (s, 3H, CH3), 3.27-3.24 (m, 2H). 
13C NMR 
(75 MHz, DMSO-d6) δ 150.3 (CIV,Ar), 150.2 (2xCHAr), 146.7 (CIV,Ar), 146.4 (CIV,Ar), 142.5 
(CIV,Ar), 139.7 (q, 
2JCF = 37 Hz, CIV,Ar), 135.8 (CIV,Ar), 133.9 (CIV,Ar), 133.9 (CHAr), 132.3 (CHAr), 
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127.9 (CIV,Ar), 126.6 (2xCHAr), 126.4 (2xCHAr), 124.0 (CHAr), 121.4 (q, 
1JCF = 266 Hz, CF3), 
121.0 (2xCHAr), 105.1 (q, 
3JCF = 2 Hz, CHAr), 72.1 (CHAr), 41.3 (CH2), 38.4 (CH3). HRMS 
(ESI+) m/z Calc. for C24H19F3N4O3 [M+H]
+ 469.1482, found 469.1480. 
General procedure C for the synthesis of 10d-10j. In a sealed glass vial were introduced the 
brominated derivative (1 equiv.), boronic acid derivative (2 equiv.), Pd(dppf)Cl2 (5 mol%), and 
K2CO3 (2 equiv.). The vessel was capped and then, evacuated and backfilled with N2 (process 
repeated 3X). The dioxane (8 mL/mmol) was introduced and the solution was heated at 80 °C 
overnight. After cooling, the mixture was extracted with ethyl acetate. The combined organic 
layers were washed with water and brine, dried over Na2SO4, filtered off, and concentrated under 
reduced pressure to afford the corresponding crude product 10d-10j. 
1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(4-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-2-
nitrophenyl)ethanol (10d). The crude product was prepared according to procedure C starting 
from 9c (94 mg, 0.24 mmol) and (1-methyl-3-trifluoromethyl-1H-pyrazol-5-yl)boronic acid (93 
mg, 0.48 mmol). After purification by column chromatography on silica gel (Petroleum 
ether/EtOAc 5:5), the pure product 10d (92 mg, 0.20 mmol, 84%) was obtained as white solid. 
m.p: 153 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.46 (d, J = 2.4 Hz, 1H), 8.13 (d, J = 1.6 Hz, 
1H), 7.86 (dd, J = 8.0, 1.6 Hz, 1H), 7.80 (d, J = 8.5 Hz, 2H), 7.73 (d, J = 1.3 Hz, 1H), 7.64 (d, J 
= 8.0 Hz, 1H), 7.44 (d, J = 8.5 Hz, 2H), 7.06 (s, 1H), 6.53 (dd, J = 2.4, 1.3 Hz, 1H), 5.54 (d, J = 
4.7 Hz, 1H, OH), 4.88-4.83 (m, 1H), 3.97 (s, 3H, CH3), 3.27-3.24 (m, 2H). 
13C NMR (75 MHz, 
DMSO-d6) δ 150.3 (CIV,Ar), 143.0 (CIV,Ar), 142.5 (CIV,Ar), 140.7 (CHAr), 139.6 (q, 
2JCF = 37 Hz, 
CIV,Ar), 138.7 (CIV,Ar), 136.7 (CIV,Ar), 133.8 (CHAr), 132.3 (CHAr), 127.8 (CIV,Ar), 127.5 (CHAr), 
126.7 (2xCHAr), 124.0 (CHAr), 121.4 (q, 
1JCF = 266 Hz, CF3), 118.1 (2xCHAr), 107.7 (CHAr), 
 32 
105.1 (q, 3JCF = 2 Hz, CHAr), 71.9 (CH), 41.2 (CH2), 38.4 (CH3). HRMS (ESI+) m/z Calc. for 
C22H18F3N5O3 [M+H]
+ 458.1435, found 458.1435. 
1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(4-(1-methyl-1H-pyrazol-4-yl)-2-nitrophenyl)ethanol (10e). 
The crude product was prepared according to procedure C starting from 9c (130 mg, 0.33 mmol) 
and 1-methylpyrazole-4-boronic acid pinacol ester (139 mg, 0.35 mmol). After purification by 
column chromatography on silica gel (Petroleum ether/EtOAc 5:5 to 2:8), the pure product 10e 
(98 mg, 0.25 mmol, 76%) was obtained as white solid. m.p: 166 °C. 1H NMR (300 MHz, 
DMSO-d6) δ 8.46 (d, J = 2.4 Hz, 1H), 8.27 (s, 1H), 8.04 (d, J = 1.6 Hz, 1H), 7.97 (s, 1H), 7,79-
7,76 (m, 3H), 7.72 (d, J = 1.3 Hz, 1H), 7.41 (d, J = 8.5 Hz, 2H), 7.40 (d, J = 7.9 Hz, 1H), 6.53 
(dd, J = 2.4, 1.3 Hz, 1H), 5.48 (d, J = 4.7 Hz, 1H, OH), 4,84-4,78 (m, 1H), 3.87 (s, 3H, CH3), 
3.17 (d, J = 6.4 Hz, 2H). 13C NMR (75 MHz, DMSO-d6) δ 150.6 (CIV,Ar), 143.1 (CIV,Ar), 140.7 
(CHAr), 138.6 (CIV,Ar), 136.4 (CHAr), 133.7 (CIV,Ar), 132.2 (CIV,Ar), 129.9 (CHAr), 128.5 (CHAr), 
128.4 (CHAr), 127.5 (CHAr), 126.7 (2xCHAr), 119.8 (CIV,Ar), 119.6 (CHAr), 118.0 (2xCHAr), 107.6 
(CHAr), 72.1 (CH), 41.3 (CH2), 38.7 (CH3). HRMS (ESI+) m/z Calc. for C21H19N5O3 [M+H]
+ 
390.1561, found 390.1559. 
1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(4-(3,5-dimethylisoxazol-4-yl)-2-nitrophenyl)ethanol (10f). 
The crude product was prepared according to procedure C starting from 9c (100 mg, 0.26 mmol) 
and 3,5-dimethylisoxazole-4-boronic acid pinacol ester (115 mg, 0.51 mmol). After purification 
by column chromatography on silica gel (Petroleum ether/EtOAc 5:5), the pure product 10f (100 
mg, 0.24 mmol, 95%) was obtained as white solid. m.p: 130 °C. 1H NMR (300 MHz, DMSO-d6) 
δ 8.46 (d, J = 2.4 Hz, 1H), 7.89 (d, J = 1.6 Hz, 1H), 7.80 (d, J = 8.5 Hz, 2H), 7.73 (d, J = 1.4 Hz, 
1H), 7.65 (dd, J = 7.8, 1.6 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.44 (d, J = 8.5 Hz, 2H), 6.53 (dd, J 
= 2.4, 1.4 Hz, 1H), 5.51 (d, J = 4.7 Hz, 1H, OH), 4,87-4,81 (m, 1H), 3.23-3.20 (m, 2H), 2.43 (s, 
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3H), 2.25 (s, 3H). 13C NMR (75 MHz, DMSO-d6) δ 166.0 (CIV,Ar), 158.0 (CIV,Ar), 150.4 (CIV,Ar), 
143.2 (CIV,Ar), 140.7 (CHAr), 138.6 (CIV,Ar), 133.7 (CHAr), 132.6 (CIV,Ar), 132.1 (CIV,Ar), 129.3 
(CHAr), 127.5 (CHAr), 126.6 (2xCHAr), 123.8 (CHAr), 118.0 (2xCHAr), 114.1 (CIV,Ar), 107.6 
(CHAr), 71.9 (CH), 41.3 (CH2), 11.3 (CH3), 10.3 (CH3). HRMS (ESI+) m/z Calc. for C22H20N4O4 
[M+H]+ 405.1557, found 405.1555. 
1-(4-(1H-1,2,4-Triazol-1-yl)phenyl)-2-(4-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-2-
nitrophenyl)ethanol (10g). The crude product was prepared according to procedure C starting 
from 9f (90 mg, 0.23 mmol) and (1-methyl-3-trifluoromethyl-1H-pyrazol-5-yl)boronic acid (90 
mg, 0.46 mmol). After purification by column chromatography on silica gel (EtOAc), the pure 
product 10g (86 mg, 0.19 mmol, 82%) was obtained as white solid. m.p: 116 °C. 1H NMR (400 
MHz, DMSO-d6) δ 9.28 (s, 1H), 8.23 (s, 1H), 8.14 (d, J = 1.8 Hz, 1H), 7.88 (dd, J = 8.1, 1.8 Hz, 
1H), 7.84 (d, J = 8.6 Hz, 2H), 7.66 (d, J = 8.1 Hz, 1H), 7.52 (d, J = 8.6 Hz, 2H), 7.07 (s, 1H), 
5.62 (d, J = 4.7 Hz, 1H, OH), 4.90-4.86 (m, 1H), 3.97 (s, 3H), 3.30-3.21 (m, 2H). 13C NMR (100 
MHz, DMSO-d6) δ 152.3 (CHAr), 150.3 (CIV,Ar), 144.8 (CHAr), 142.5 (CIV,Ar), 142.2 (CIV,Ar), 
139.6 (q, 2JCF = 37 Hz, CIV,Ar), 135.7 (CIV,Ar), 133.9 (CIV,Ar), 133.8 (CHAr), 132.3 (CHAr), 127.9 
(CIV,Ar), 126.9 (2xCHAr), 124.1 (CHAr), 121.4 (q, 
1JCF = 266 Hz, CF3), 120.1 (2xCHAr), 105.2 (q, 
3JCF = 2 Hz, CHAr), 71.9 (CH), 41.2 (CH2), 38.5 (CH3). HRMS (ESI+) m/z Calc. for 
C21H17F3N6O3 [M+H]
+ 459.1387, found 459.1385. 
1-(4-(1H-1,2,4-Triazol-1-yl)phenyl)-2-(4-(1-methyl-1H-pyrazol-4-yl)-2-nitrophenyl)ethanol 
(10h). The crude product was prepared according to procedure C starting from 9f (90 mg, 0.23 
mmol) and 1-methylpyrazole-4-boronic acid pinacol ester (96 mg, 0.46 mmol). After purification 
by column chromatography on silica gel (100% EtOAc to EtOAc/MeOH (98:2)), the pure 
product 10h (86 mg, 0.22 mmol, 96%) was obtained as yellow solid. m.p: 189 °C. 1H NMR (300 
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MHz, DMSO-d6) δ 9.26 (s, 1H), 8.28 (s, 1H), 8.22 (s, 1H), 8.05 (s, 1H), 7.97 (s, 1H), 7.80 (d, J = 
8.2 Hz, 2H), 7.78 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 8.2 Hz, 2H), 7.40 (d, J = 8.0 Hz, 1H), 5.54 (d, 
J = 4.6 Hz, 1H, OH), 4.87-4.81 (m, 1H), 3.87 (s, 3H), 3.17 (d, J = 6,1 Hz, 2H). 13C NMR (75 
MHz, DMSO-d6) δ 152.2 (CHAr), 150.6 (CIV,Ar), 144.9 (CHAr), 142.1 (CIV,Ar), 136.4 (CHAr), 
135.6 (CIV,Ar), 133.7 (CIV,Ar), 132.3 (CIV,Ar), 129.8 (CHAr), 128.5 (CHAr), 128.5 (CHAr), 126.9 
(2xCHAr), 119.8 (CIV,Ar), 119.6 (CHAr), 119.0 (2xCHAr), 72.0 (CH), 41.2 (CH2), 39.2 (CH3). 
HRMS (ESI+) m/z Calc. for C20H18N6O3 [M+H]
+ 391.1513, found 391.1513. 
1-(4-(1H-1,2,4-Triazol-1-yl)phenyl)-2-(4-(3,5-dimethylisoxazol-4-yl)-2-nitrophenyl)ethanol 
(10i). The crude product was prepared according to procedure C starting from 9f (90 mg, 0.23 
mmol) and 3,5-dimethylisoxazole-4-boronic acid pinacol ester (103 mg, 0.46 mmol). After 
purification by column chromatography on silica gel (100% EtOAc), the pure product 10i (50 
mg, 0.12 mmol, 54%) was obtained as yellow solid. m.p: 153 °C. 1H NMR (300 MHz, DMSO-
d6) δ 9.26 (s, 1H), 8.22 (s, 1H), 7.90 (d, J = 1.5 Hz, 1H), 7.82 (d, J = 8.5 Hz, 2H), 7.66 (dd, J = 
7.9, 1.5 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.51 (d, J = 8.5 Hz, 2H), 5.57 (d, J = 4.7 Hz, 1H, OH), 
4.90-4.85 (m, 1H), 3.26-3.16 (m, 2H), 2.43 (s, 3H), 2.25 (s, 3H). 13C NMR (75 MHz, DMSO-d6) 
δ 166.0 (CIV,Ar), 158.0 (CIV,Ar), 152.3 (CHAr), 150.4 (CIV,Ar), 144.9 (CHAr), 142.1 (CIV,Ar), 135.6 
(CIV,Ar), 133.7 (CHAr), 132.6 (CIV,Ar), 132.0 (CIV,Ar), 129.4 (CHAr), 126.9 (2xCHAr), 123.9 (CHAr), 
119.1 (2xCHAr), 114.1 (CIV,Ar), 71.9 (CH), 41.2 (CH2), 11.3 (CH3), 10.3 (CH3). HRMS (ESI+) 
m/z Calc. for C21H19N5O4 [M+H]
+ 406.1510, found 406.1506. 
1-(4-(1H-1,2,4-Triazol-1-yl)phenyl)-2-(2-nitro-4-(thiazol-5-yl)phenyl)ethanol (10j). The 
crude product was prepared according to procedure C starting from 9f (108 mg, 0.28 mmol) and 
thiazol-5-ylboronic acid pinacol ester (133 mg, 0.55 mmol). After purification by column 
chromatography on silica gel (100% EtOAc to EtOAc/MeOH (98:2)), the pure product 10j (95 
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mg, 0.24 mmol, 88%) was obtained as white solid. m.p: 182 °C. 1H NMR (300 MHz, DMSO-d6) 
δ 9.26 (s, 1H), 9.16 (s, 1H), 8.47 (s, 1H), 8.22 (s, 1H), 8.19 (s, 1H), 7.92 (d, J = 7.9 Hz, 1H), 7.82 
(d, J = 8.0 Hz, 2H), 7.52 (d, J = 7.9 Hz, 1H), 7.49 (d, J = 8.0 Hz, 2H), 5.58 (d, J = 4,1 Hz, 1H, 
OH), 4.88-4.84 (m, 1H), 3.29-3.23 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 154.6 (CHAr), 
152.3 (CHAr), 150.6 (CIV,Ar), 144.7 (CHAr), 142.1 (CIV,Ar), 140.8 (CIV,Ar), 136.2 (CHAr), 135.6 
(CIV,Ar), 134.2 (CHAr), 132.5 (CIV,Ar), 130.3 (CIV,Ar), 130.1 (CHAr), 126.9 (2xCHAr), 121.4 
(CHAr), 119.1 (2xCHAr), 71.9 (CH), 41.2 (CH2). HRMS (ESI+) m/z Calc. for C19H15N5O3S 
[M+H]+ 394.0968, found 394.0967. 
Synthesis of Mosher esters 11a and 11b (Figure A, Supporting information). 
Dimethylaminopyridine (DMAP) (0.5 mg, 0.0044 mmol) was added to a mixture of 10h’ or 
10h’’ (17.2 mg, 0.044 mmol), (R)-methoxyphenylacetic acid (MPA) (7.0 mg, 0.044 mmol) and 
N,N-dicyclohexylcarbodiimide (DCC) (9.0 mg, 0.044 mmol) in anhydrous CH2Cl2 (3 mL) under 
Ar stream. The reaction mixture was stirred at 25 °C for 12 h, cooled to 0 °C and filtered. The 
filtrate was evaporated and purified by column chromatography on silica gel (100% EtOAc) to 
furnish Mosher esters 11a and 11b. 
Mosher ester 11a: Yield 65%. 1H NMR (400 MHz, DMSO-d6) δ 9.27 (s, 1H), 8.34 (s, 1H), 8.23 
(s, 1H), 8.14 (d, J = 1.8 Hz, 1H), 8.02 (s, 1H), 7.81 (dd, J = 8.0, 1.8, 1H), 7.71 (d, J = 8.6 Hz, 
2H), 7.44 (d, J = 8.1 Hz, 1H), 7.35-7.30 (m, 5H), 7.18 (d, J = 8.6 Hz, 2H), 6.06 (t, J = 7.5 Hz, 
1H), 4.85 (s, 1H), 3.88 (s, 3H), 3.19 (s, 3H), 1.06 (t, J = 6.9 Hz, 2H).  
Mosher ester 11b: Yield 73%. 1H NMR (400 MHz, DMSO-d6) δ 9.32 (s, 1H), 8.31 (s, 1H), 8.26 
(s, 1H), 8.05 (d, J = 1.8 Hz, 1H), 7.99 (s, 1H), 7.87 (d, J = 8.6 Hz, 2H), 7.55-7.52 (m, 3H), 7.31-
7.25 (m, 5H), 7.11 (d, J = 8.1 Hz, 1H), 6.06-6.03 (m, 1H), 4.92 (s, 1H), 3.90 (s, 3H), 3.19 (s, 
3H), 1.06 (t, J = 7.0 Hz, 2H).  
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Enantioselective HPLC.  
Enantioselective HPLC analyses were performed by using stainless-steel Chiralpak IG (250 
mm × 4.6 mm i.d.) and Chiralpak IG-3 (250 mm × 250 mm × 10 mm i.d.) (Daicel, Chemical 
Industries, Tokyo, Japan) columns. HPLC-grade solvents were used as supplied by Aldrich 
(Milan, Italy). The HPLC apparatus consisted of a PerkinElmer (Norwalk, CT, USA) 200 LC 
pump equipped with a 542 Rheodyne (Cotati, CA, USA) injector, a 1000 μL sample loop, a 
HPLC Perkin-Elmer oven and a Perkin-Elmer 290 detector. The signal was acquired and 
processed by Clarity software (DataApex, Prague, The Czech Republic).  
Circular dichroism.  
The CD spectra of the enantiomers isolated on a semipreparative scale, dissolved in ethanol 
(concentration about 0.3 mg/mL) in a quartz cell (0.1 cm path length) at 25 °C, were measured 
by using a Jasco (Jasco, Ishikawa-cho, Hachioji City, Tokyo, Japan) model J-700 
spectropolarimeter in the 400−220 nm spectral range. The spectra were average computed over 
three instrumental scans, and the intensities are presented in terms of terms of ellipticity values 
(mdeg). 
Biological assays.  
Cells and virus. HeLa Rh cells were grown in DMEM (Gibco) supplemented with 10% heat-
inactivated fetal bovine serum (FBS, Integro), and 0.075 % NaHCO3 (Gibco). Cells were grown 
at 37 °C in a 5% CO2 incubator at 95-99% relative humidity. RV-A02, RV-A85, RV-A89, RV-
B14, RV-B42 and RV-B70 were kindly provided by K. Andries (Janssen Pharmaceutica, Beerse, 
Belgium). RV-A08 and RV-A28 were kindly provided by Michaele Schmidtke 
(Universitätsklinikum, Jena, Germany). All RVs were cultivated in HeLa Rh cells in the 
presence of 30 mM MgCl2. 
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Cell-based antiviral assay. The antiviral activity of the synthesized compounds was evaluated in 
a cell-based antiviral assay with MTS read-out ([3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]). In this assay, the (residual) 
metabolic activity of treated, infected cells was quantified, representing cell survival or reduction 
of virus-induced cytopathic effects (CPE), and thus the antiviral effect of a compound. 
Rhinovirus assays were performed in 96-well plate format, using DMEM supplemented with 2% 
FBS, 0.075% NaHCO3 and 30 mM MgCl2. Briefly, a serial dilution of the compound was added 
to cells grown to confluence in 96-well microtiter plates, followed by infection with a low virus 
inoculum. The cultures were incubated for 3 days at 35 °C until complete CPE was observed in 
the untreated, infected virus control condition (VC). After removal of the medium from each 
well, 100 μL of a 5% MTS-phenazine solution in phenol red-free MEM was added. Following 
incubation for 1 h, raw OD values were collected using a microtiter plate reader (Safire, Tecan). 
Values were converted to percentage of controls and the 50% effective concentration (EC50, 
defined as the concentration of compound that should offer 50% protection against virus-induced 
CPE), was calculated from the dose-response curve using logarithmic interpolation. In addition, 
the assays were inspected by light microscope and the adverse effect of the compound on the 
cells was quantified by cell scoring, from which the CC50 (concentration at which 50% cytotoxic 
effect is observed) was calculated using logarithmic interpolation. 
Time-of-drug addition assay. HeLa Rh cells were allowed to adhere overnight in 96-well cell 
culture plates. The next day, 1 µM compound 10e, (S)-10e, 10h, (R)-10h and pleconaril 1 were 
added 2 hours before infection, at the time of infection or at 2, 4 or 6 hours after infection with 
RV-B14. Virus-infected, untreated cells were used as controls. At 8 h post-infection, supernatans 
was removed and the cells were lysed using Cell-to-cDNA lysis buffer (Thermo Fisher 
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Scientific). After an additional incubation at 75 °C for 15 min to inactivate DNases, intracellular 
viral RNA was quantified by qRT-PCR (iTaq™ Universal SYBR® Green One-Step Kit, Bio-
Rad) using following primers: 5’-GAAACACGGACACCCAAAGTA-3’ and 5’-
CGGCCCCTGAATGCGGCTAA-3’ (Integrated DNA technologies) and PCR program: 10 min 
at 50 °C, 3 min at 95 °C and 40 cycles of 15 s at 95 °C and 1 min at 60 °C (Applied Biosystems 
7500 Fast Real-Time PCR system). A dilution series of gBlocks (Integrated DNA technologies) 
was included as standards and RNA content was quantified as genome equivalents per sample. 
Resistance selection by passaging. HeLa cells grown to confluence in 24-well microtiter plate 
were infected with wild-type RV-B14 in the presence of 10e, 10h or 1 at a concentration of 4x, 
2x or 1x their in vitro EC50. When CPE was visible in the virus control (no compound), all the 
wells were scored for visible CPE. Next, the cell supernatant (diluted 1:10) was transferred to a 
24-well plate with freshly seeded HeLa cells in the presence of the compound and incubated as 
before. After four passages, the putative resistant virus was sequenced by Sanger sequencing. 
Briefly, viral RNA was isolated using Nucleospin© RNA virus (Macherey-Nagel). Next, a cDNA 
fragment covering the VP1 coding sequence was produced using a one-step RT-PCR kit 
(Qiagen) and RV-B14-specific primers (FP 5’-CCTTATCCAGTGCTAAACTC-3’ and RP 5’-
GCCCGACCCCTTTCATCAC-3’). cDNA sequences were analysed by Macrogen Inc.  
Micronucleus tests. 
Cell cultures and metabolic activation mixture (S9 mix). Chinese Hamster Ovary cells (CHO-
K1, ATCC) were used for the micronucleus assay. They were maintained in Mc Coy’s 5A 
medium (Sigma) supplemented with 10% foetal calf serum, 1 mM glutamine and penicilline-
streptomycine (100 U/ml-10 µg/ml) and incubated during 24 hours at 37 °C in humidified 
atmosphere containing 5% CO2. The liver homogenate used for metabolic activation (S9) was 
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prepared from male Sprague-Dawley rats treated with Aroclor 1254 (500 mg/kg body weight). 
The S9 mix used for the test was a mixture of S9 and a solution of NADPH generating factors 
(Mix).The final composition of the S9 mix included included 1% S9, 0.5 mM G6P and 0.4 mM 
NADP. 
Micronucleus assay on CHO-K1 cells. The capacities of test materials to induce micronuclei 
were assessed according to the protocol described by Kirsch-Volders et al.45 All the assays were 
conducted in duplicate. The CHO-K1 cells, suspended in Mac Coys'5A medium, were 
transferred into Labteck wells at a concentration of 100,000 cells/ml, and incubated for 24 hours 
at 37 °C in CO2 (5% ). When the test was performed without metabolic activation, the test 
substances were added into cell cultures at concentrations previously defined. A negative control 
containing culture medium, a solvent control containing 1% DMSO and a positive control 
containing 0.6 µg/ml of mitomycin C were added. When the assay was performed in the 
presence of metabolic activation, S9 mix metabolizing mixture was added to cell cultures at a 
concentration of 10%. Then the test substances were added to the cell cultures at concentrations 
previously defined. A negative control containing culture medium, a solvent control containing 
1% DMSO and a positive control containing 5 µg/ml of benzo-a-pyrene were added. After 3 
hours of incubation at 37 °C in CO2 (5%), the culture medium was removed, the cells were 
rinsed with phosphate buffered saline (PBS), and then returned to culture in McCoy's 5A 
medium containing 3 µg/ml of cytochalasin B. After a 21-hour incubation period at 37 °C, cells 
were rinsed with phosphate buffered saline (PBS), fixed with methanol and stained with 10% 
Giemsa for 20 minutes. 
Analysis of results. Cells were examined under a microscope at x1000 magnification. The 
antiproliferative activity of test substances was estimated by counting the number of binucleated 
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cells relative to the number of mononucleated cells on a total of 500 cells for each dose (250 
cells counted per well). The proliferation index (Cytokinesis Blocked Proliferative Index CBPI) 
was calculated using the following formula: 
 
   
BI : number of binucleated cells; MONO : number of mononucleated cells 
The cytostasis index (CI%), i.e. the percentage of cell replication inhibition, was calculated 
using the following formula: CI% : 100- {100x(CBPItest material-1)/(CBPIsolvent control-1). 
After this step, only the doses inducing a decrease of less than 55 ± 5% of CI% as compared to 
the negative control were taken into account for counting micronuclei. The rates of micronuclei 
were evaluated for the presence of independent nuclear core entities in 1000 binucleated cells per 
well, which corresponds to 2000 cells examined by test substance dose.  
Micronuclei were identified as small nuclei well differentiated from cell nucleus, stained in the 
same manner and having a diameter less than one third of that of the cell nucleus. Micronuclei 
rates obtained for different doses of test substances were compared to the negative control by a 
x2 test. The assay was considered positive if: 
a dose-response relationship was obtained between the rate of micronuclei and the doses 
tested, 
at least one of these doses induced a statistically significant increase (P < 0.05) in the number 
of micronucleated cells as compared to the negative control. 
Modelling and docking analysis 
All molecular modelling studies were performed on a MacPro dual 2.66 GHz Xeon running 
Ubuntu 14LTS. The RV capsid structures were downloaded from PDB [http://www.rcsb.org/.]: 
4PDW;39 1NCQ;47 3VDD.32 Hydrogen atoms were added to the protein, using Maestro48 protein 
500
*2 MONOBI
CBPI


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preparation wizard49 and minimized, keeping all the heavy atoms fixed until a rmsd gradient of 
0.05 kcal.mol-1.Å-1 was reached. Ligand structures were built with Maestro and minimized using 
the MMFF94x force field until a rmsd gradient of 0.05 kcal.mol-1.Å-1 was reached. The docking 
simulations were carried out by Plants.50,51 The homology models for studied isotypes were built 
by Prime.52The sequences of the VP1 proteins were available at the Uniprot database 
[www.uniprot.org]: RV-B70 Q7T5Z4; RV-B42 Q7T622_9ENTO; RV-A2 Q7T662_HRV2; RV-
A8 Q7T656_9ENTO; RV-A85 Q7T5X9_9ENTO; RV-A89 Q7T5X5_HRV89; Hr_A28 
Q7T636_9ENTO Uniprot code respectively. The high identity among the references and the 
built models led as to avoid any further models optimizations. The images depicted in the 
manuscript were generated by Pymol.53 
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Throughput Screening; ICAM-1, intercellular adhesion molecule 1; (rac), racemic; RV, 
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